Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010

Géri, Guillaume; Maynard, Marianne; Eric, Rosenthal; Fontaine, Hélène; Lacombe, Karine; Slama, Laurence; Goujard, Cécile; Loustaud‐Ratti, Véronique; Bergmann, Jean‐François; Morlat, Philippe; Vittecoq, D.; Alric, Laurent; Cacoub, Patrice

doi:10.1111/liv.12388

Cited by 5 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In France, an observational multicentre study showed an increase in number of newly referred patients with cirrhosis with 7.4% of the patients in 1995, 10.4% in 2001 and 16.1% in 2010. Even though an increase was observed, this percentage in France was lower than in the current study [54]. This is probably due to the fact that, in contrast to the Netherlands as well as many other countries in Europe, France has been actively screening and treating patients over the last two decades.…”

Section: Discussioncontrasting

confidence: 90%

Epidemiological Trends among the Population with Chronic HCV Infection in the Netherlands

Maan

Toes‐Zoutendijk²,

Bj³

et al. 2015

Antiviral Therapy

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 90%

Epidemiological Trends among the Population with Chronic HCV Infection in the Netherlands

Maan

Toes‐Zoutendijk²,

Bj³

et al. 2015

Antiviral Therapy

View full text Add to dashboard Cite

show abstract

“…Results from one study site showed HCV viral loads significantly lower than those from the other sites by analysis of variance (ANOVA). That site was in France, where the level of access to antiviral treatment is high; the lower viral loads seen at that site were likely due to higher treatment rates as opposed to a methodological difference (11,12). One drawback of this work was that most samples were tested retrospectively after being frozen, although samples were tested on each platform from the same freezethaw cycle.…”

Section: Discussionmentioning

confidence: 99%

Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay

McHugh

Chevaliez³

et al. 2017

J Clin Microbiol

View full text Add to dashboard Cite

Viral load monitoring for hepatitis C virus (HCV) is necessary to diagnose infection and monitor response to therapy, but the tests involved are currently confined to specialist institutions. There is a need for a fast, accurate assay with limited operator input to enhance the access to viral load monitoring. We evaluated the quantification of HCV RNA in serum and plasma by the Cepheid Xpert HCV Viral Load assay in comparison to the Abbott RealTie HCV assay. Serum and plasma samples were gathered from HCV-infected individuals at four international sites. These were tested with the Xpert HCV Viral Load assay, and results were compared to quantification by the Abbott RealTie HCV assay. An external quality assessment panel of eight samples was also tested. In total, 614 samples were analyzed in the study, and the qualitative results agreed on the two platforms for 588 (95.8%) samples. Further analysis of 396 samples quantified by both tests showed strong correlation (correlation coefficient = 0.99) across the quantifiable range, with Bland-Altman plot data showing a mean difference (±1.96 standard deviation) of 0.03 ± 0.44 log IU/ml. In the external quality assessment panel, the Xpert HCV Viral Load assay results (quantified in log IU per milliliter) were within 1 standard deviation of the target value for all but one sample, which was also similarly misquantified by the Abbott RealTime HCV assay. The Xpert HCV Viral Load assay performs well compared to a market-leading HCV viral load test and should be considered for instances where rapid near-to-patient testing is required.

show abstract

“…New infections mainly occur in active injecting DU, where the estimated incidence is 11.2/100 person-years [ 23 ]. The most frequent genotypes (GT) are GT1 (56–61%), GT3 (19%) and GT4 (9–17%) depending on patient recruitment [ 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015

et al. 2017

View full text Add to dashboard Cite

BackgroundThe last decade was marked by major advances in HCV treatment with the introduction of first wave protease inhibitors (1st-wave PIs, telaprevir or boceprevir) in 2011 and second direct-acting antivirals (2nd-wave DAAs) in 2014, that followed low effective pegylated interferon α / ribavirin bitherapy. We estimated the number of patients initiating HCV treatment in France between 2007 and 2015 according to the type of therapy, described their demographical characteristics, and estimated how many were cured with 2nd-wave DAAs in 2014–2015.MethodsIndividual data from the national health insurance information system were analysed. HCV treatment initiation was defined as a drug reimbursement in the absence of any reimbursement for the same drug in the previous six weeks.ResultsBetween 2007 and 2015, 72,277 patients initiated at least one HCV treatment. The annual number of patients initiating treatment decreased from 2007 (~13,300) to 2010 (~10,000). It then increased with the introduction of 1st-wave PIs (~12,500 in 2012), before decreasing again in 2013 (~8400). A marked increase followed upon the approval of 2nd-wave DAAs in 2014 (~11,600). Approximately, 8700 and 14,700 patients initiated 2nd-wave DAAs in 2014 and 2015, respectively, corresponding to an estimated 20,300 cured patients in 2014–2015.Patients initiating HCV treatment were mostly male (~65% throughout the 9-year period). Women were older than men (mean age: 55.0 vs. 48.9). Increasing age was associated with more advanced treatment. Among patients initiating 2nd-wave DAAs, the proportions of those under 40 and over 79 years old increased between 2014 and 2015, whereas the proportion of those previously treated for HCV 2007 onwards declined.ConclusionsSuccessive advances in HCV treatment have been rapidly and widely implemented in France. With the announcement of universal access to DAAs in mid-2016 and price reductions, access to 2nd-wave DAAs is expected to expand even more.

show abstract

Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010

Cited by 5 publications

References 47 publications

Epidemiological Trends among the Population with Chronic HCV Infection in the Netherlands

Epidemiological Trends among the Population with Chronic HCV Infection in the Netherlands

Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay

Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015

Contact Info

Product

Resources

About